Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2009

View Archived Issues

Novel PDE inhibitors in development at Kyorin for the treatment of respiratory disorders

Schering-Plough announces the development of Aurora kinase inhibitors

Roche claims novel PI3K inhibitors with potential as anticancer agents

New chemokine CXCR5 receptor antagonists prepared and tested at sanofi-aventis

Kyowa Hakko Kirin describes novel antitumor agents

Lipoic acid slows Alzheimer's disease progression

Novartis and Medicines for Malaria Venture launch Coartem dispersible

Oasmia's Paclical shows promising results in patients with severe cancer

Pixantrone increases progression-free survival in non-Hodgkin's lymphoma trial

Amgen reviews Q4 progress

HPIV3/EboGP Ebola vaccine enhanced and tested in vivo

Cripto blockade enhances embryonic stem cell transplant in Parkinson's disease model

Gelnique gel approved by the FDA for overactive bladder

Medarex to initiate trial for first antibody-drug conjugate, MDX-1203

Chelsea initiates phase II droxidopa trial in fibromyalgia

Verona obtains regulatory approval for clinical trial of its antiasthma drug RPL-554

Duska Therapeutics changes company name to Cordex Pharma

Omeros receives milestone payment from SMRI for development of PDE-10 inhibitors

Kringle receives approval for ChronSeal CTA and signs option agreement with Maruho

Alfacell conducts pre-NDA meeting with FDA regarding Onconase for UMM

Novacea stockholders approve merger with Transcept

The Medicines Company initiates tender offer for all outstanding shares of Targanta

FDA allows Clinuvel to begin U.S. clinical trials of afamelanotide

Boston Scientific's Taxus Liberte drug-eluting stent approved in Japan

Can-Fite completes patient enrollment in phase II CF-101 dry eye syndrome trial

FDA advisory panel to review pegloticase BLA for treatment-failure gout

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...